FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796268889> ?p ?o ?g. }

• W2796268889 endingPage "2129" @default.
• W2796268889 startingPage "2123" @default.
• W2796268889 abstract "Objective To compare the effects of inhaled milrinone and levosimendan on pulmonary and systemic hemodynamics in patients with pulmonary hypertension. Design Prospective, double-blind, randomized controlled study. Setting Tertiary care cardiac institute with 650 beds. Participants The study comprised 150 adult patients with pulmonary hypertension undergoing mitral valve surgery. Interventions Patients were assigned randomly into 1 of the following 3 groups: milrinone (M), levosimendan (L), or control (C); n = 50 per group. In group M, inhaled milrinone (50 µg/kg); in group L, inhaled levosimendan (24 µg/kg); and in group C, normal saline was administered when the patient arrived in the recovery room. Pre-inhalation and post-inhalation hemodynamics (mean arterial pressure [MAP], pulse rate, and systemic vascular resistance [SVR]) were noted until 24 hours of inhalation of the drug. The change in pulmonary artery pressures (pulmonary artery systolic pressure [PASP] and mean pulmonary artery pressure [MPAP]) and the duration for which they remained decreased compared with the control group, were noted. Measurements and Main Results MAP, pulse rate, and SVR were comparable in the 3 groups at various time intervals. PASP and MPAP decreased comparably after inhalation of levosimendan and milrinone. However, they reached levels near the control group values after 2.5 to 3 hours in group L and after 0.5 hours in group M. Conclusions Because inhaled levosimendan causes a decrease in PASP and MPAP without causing a decrease in SVR and MAP, the authors conclude that inhaled levosimendan is a selective pulmonary vasodilator. It is as effective as milrinone in reducing pulmonary artery pressures. In addition, it has advantage over inhaled milrinone because it is has a longer duration of action. To compare the effects of inhaled milrinone and levosimendan on pulmonary and systemic hemodynamics in patients with pulmonary hypertension. Prospective, double-blind, randomized controlled study. Tertiary care cardiac institute with 650 beds. The study comprised 150 adult patients with pulmonary hypertension undergoing mitral valve surgery. Patients were assigned randomly into 1 of the following 3 groups: milrinone (M), levosimendan (L), or control (C); n = 50 per group. In group M, inhaled milrinone (50 µg/kg); in group L, inhaled levosimendan (24 µg/kg); and in group C, normal saline was administered when the patient arrived in the recovery room. Pre-inhalation and post-inhalation hemodynamics (mean arterial pressure [MAP], pulse rate, and systemic vascular resistance [SVR]) were noted until 24 hours of inhalation of the drug. The change in pulmonary artery pressures (pulmonary artery systolic pressure [PASP] and mean pulmonary artery pressure [MPAP]) and the duration for which they remained decreased compared with the control group, were noted. MAP, pulse rate, and SVR were comparable in the 3 groups at various time intervals. PASP and MPAP decreased comparably after inhalation of levosimendan and milrinone. However, they reached levels near the control group values after 2.5 to 3 hours in group L and after 0.5 hours in group M. Because inhaled levosimendan causes a decrease in PASP and MPAP without causing a decrease in SVR and MAP, the authors conclude that inhaled levosimendan is a selective pulmonary vasodilator. It is as effective as milrinone in reducing pulmonary artery pressures. In addition, it has advantage over inhaled milrinone because it is has a longer duration of action." @default.
• W2796268889 created "2018-04-13" @default.
• W2796268889 creator A5004123493 @default.
• W2796268889 creator A5012542537 @default.
• W2796268889 creator A5061114416 @default.
• W2796268889 creator A5061490321 @default.
• W2796268889 creator A5076200640 @default.
• W2796268889 date "2018-10-01" @default.
• W2796268889 modified "2023-10-13" @default.
• W2796268889 title "The Effect of Inhaled Milrinone Versus Inhaled Levosimendan in Pulmonary Hypertension Patients Undergoing Mitral Valve Surgery — A Pilot Randomized Double-Blind Study" @default.
• W2796268889 cites W1965098193 @default.
• W2796268889 cites W1975180879 @default.
• W2796268889 cites W1975314112 @default.
• W2796268889 cites W1975443612 @default.
• W2796268889 cites W1977492517 @default.
• W2796268889 cites W1985039632 @default.
• W2796268889 cites W2001981626 @default.
• W2796268889 cites W201106316 @default.
• W2796268889 cites W2021035905 @default.
• W2796268889 cites W2023833625 @default.
• W2796268889 cites W2026598486 @default.
• W2796268889 cites W2040624527 @default.
• W2796268889 cites W2042298649 @default.
• W2796268889 cites W2051270428 @default.
• W2796268889 cites W2069981982 @default.
• W2796268889 cites W2075359024 @default.
• W2796268889 cites W2090192717 @default.
• W2796268889 cites W2158749167 @default.
• W2796268889 cites W2243939347 @default.
• W2796268889 cites W2313879807 @default.
• W2796268889 doi "https://doi.org/10.1053/j.jvca.2018.04.022" @default.
• W2796268889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30098861" @default.
• W2796268889 hasPublicationYear "2018" @default.
• W2796268889 type Work @default.
• W2796268889 sameAs 2796268889 @default.
• W2796268889 citedByCount "11" @default.
• W2796268889 countsByYear W27962688892019 @default.
• W2796268889 countsByYear W27962688892020 @default.
• W2796268889 countsByYear W27962688892021 @default.
• W2796268889 countsByYear W27962688892022 @default.
• W2796268889 countsByYear W27962688892023 @default.
• W2796268889 crossrefType "journal-article" @default.
• W2796268889 hasAuthorship W2796268889A5004123493 @default.
• W2796268889 hasAuthorship W2796268889A5012542537 @default.
• W2796268889 hasAuthorship W2796268889A5061114416 @default.
• W2796268889 hasAuthorship W2796268889A5061490321 @default.
• W2796268889 hasAuthorship W2796268889A5076200640 @default.
• W2796268889 hasConcept C126322002 @default.
• W2796268889 hasConcept C139940330 @default.
• W2796268889 hasConcept C164705383 @default.
• W2796268889 hasConcept C178853913 @default.
• W2796268889 hasConcept C2776645727 @default.
• W2796268889 hasConcept C2776954882 @default.
• W2796268889 hasConcept C2777335384 @default.
• W2796268889 hasConcept C2778198053 @default.
• W2796268889 hasConcept C2780930700 @default.
• W2796268889 hasConcept C2780940725 @default.
• W2796268889 hasConcept C42219234 @default.
• W2796268889 hasConcept C58245268 @default.
• W2796268889 hasConcept C71924100 @default.
• W2796268889 hasConceptScore W2796268889C126322002 @default.
• W2796268889 hasConceptScore W2796268889C139940330 @default.
• W2796268889 hasConceptScore W2796268889C164705383 @default.
• W2796268889 hasConceptScore W2796268889C178853913 @default.
• W2796268889 hasConceptScore W2796268889C2776645727 @default.
• W2796268889 hasConceptScore W2796268889C2776954882 @default.
• W2796268889 hasConceptScore W2796268889C2777335384 @default.
• W2796268889 hasConceptScore W2796268889C2778198053 @default.
• W2796268889 hasConceptScore W2796268889C2780930700 @default.
• W2796268889 hasConceptScore W2796268889C2780940725 @default.
• W2796268889 hasConceptScore W2796268889C42219234 @default.
• W2796268889 hasConceptScore W2796268889C58245268 @default.
• W2796268889 hasConceptScore W2796268889C71924100 @default.
• W2796268889 hasIssue "5" @default.
• W2796268889 hasLocation W27962688891 @default.
• W2796268889 hasLocation W27962688892 @default.
• W2796268889 hasOpenAccess W2796268889 @default.
• W2796268889 hasPrimaryLocation W27962688891 @default.
• W2796268889 hasRelatedWork W1996127841 @default.
• W2796268889 hasRelatedWork W2091575018 @default.
• W2796268889 hasRelatedWork W2129350691 @default.
• W2796268889 hasRelatedWork W2252635017 @default.
• W2796268889 hasRelatedWork W2364251493 @default.
• W2796268889 hasRelatedWork W2809044574 @default.
• W2796268889 hasRelatedWork W2972612328 @default.
• W2796268889 hasRelatedWork W3032790161 @default.
• W2796268889 hasRelatedWork W4249643383 @default.
• W2796268889 hasRelatedWork W2519109828 @default.
• W2796268889 hasVolume "32" @default.
• W2796268889 isParatext "false" @default.
• W2796268889 isRetracted "false" @default.
• W2796268889 magId "2796268889" @default.
• W2796268889 workType "article" @default.